Brind.

Moleculin Biotech, Inc. announced that Annamycin showed efficacy against HCC models, and Waldemar Priebe serves on the Scientific Advisory Board.

3 reports, 2 independent Updated Jul 31
Gone quiet
Reports
3
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Moleculin Biotech, Inc. announced that Annamycin showed efficacy against HCC models, and Waldemar Priebe serves on the Scientific Advisory Board.

Who's involved

What this event is mainly about
Waldemar PriebeHCC

How it developed

Newest first. Tap a step to see who reported it.
  1. Annamycin is entering clinical trials and recruitment phases in Europe.1 source
  2. Moleculin Biotech, Inc. announced that Annamycin showed efficacy against HCC models, and Waldemar Priebe serves on the Scientific Advisory Board.1 source
  3. FDA approved Annamycin pediatric study and provided feedback.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • benzinga.com
  • GlobeNewswireMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment Presented data highlights the potential of Annamycin for treating broad range of human cancers, inclu
  • Unknown outlet